Skip to content
    BIIB
    Earnings call· Sep 2025(Q3 FY25)

    BIOGEN INC. BIIB

    Oct 30, 2025 Source

    Executive summary

    Biogen Q3 FY25 — Strong Launch Product Growth and Pipeline Advancement

    Biogen delivered a strong quarter, driven by robust growth in its launch products which continue to offset the decline in the legacy MS portfolio. The company is strategically advancing its late-stage pipeline with high conviction, while also expanding its early-stage assets through disciplined business development. Efforts are focused on market creation for new therapies and optimizing the care pathway for Alzheimer's patients, positioning Biogen for sustainable long-term growth.

    Highlights

    5

    • Launch products revenue grew 67% year-on-year to $257 million in Q3 FY25, more than offsetting MS decline year-to-date.

    • LEQEMBI global sales reached $121 million, demonstrating strong sequential global demand growth.

    • SKYCLARYS revenue increased 30% year-over-year and is now available in 34 markets globally.

    • ZURZUVAE achieved 150% revenue growth year-over-year, with 80% of prescriptions written as first-line therapy.

    • Litifilimab Phase III studies for SLE are fully enrolled, accelerating expected readouts to H2 2026.

    Concerns

    4

    • LEQEMBI Q3 FY25 sales were impacted by a prior-quarter inventory build in China, resulting in negligible sales recognized for China in Q3 and expected in Q4.

    • SKYCLARYS U.S. Q3 FY25 revenue was impacted by a $6 million adjustment related to channel mix due to IRA changes to Medicare.

    • TECFIDERA experienced accelerated generic erosion in Europe, particularly in Germany, leading to a $28 million sequential net decrease in Q3 FY25.

    • A $100 million pretax charge was accrued in Q3 FY25 related to a judgment on Genentech's claim for past TYSABRI royalties and interest.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2025 Revenue Growth
    Roughly flat to up 1%
    high materiality
    High
    Full-year 2025 Non-GAAP Diluted EPS
    Updated to reflect stronger business outlook and investment for growth
    high materiality
    High
    Q4 2025 Contract Manufacturing Revenue
    $10 million to $20 million
    medium materiality
    High
    Q4 2025 Operating Expenses
    Approximately $1.1 billion
    medium materiality
    High
    Fit-for-Growth Gross Savings
    $1 billion
    high materiality
    High
    Fit-for-Growth Net Savings
    $800 million
    high materiality
    High
    Full-year 2025 Global SPINRAZA Revenue
    Relatively similar to 2024
    medium materiality
    High
    High-dose SPINRAZA PDUFA Date
    April 2026
    medium materiality
    High

    Segment performance

    6
    SegmentRevenueYoYQoQMargin
    Launch Products (Global)
    Strong performance from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, more than offsetting MS decline year-to-date.
    		$257M67%——
    LEQEMBI (Global)
    Continued strong sequential global demand growth. Q3 sales impacted by Q2 inventory build in China, with half drawn down in Q3. IQLIK subcutaneous auto-injector for maintenance launched in U.S.
    Prescriber base growth: 14% quarter-over-quarterNew patients captured: ~half of all new anti-amyloid patients in 2025Market share: Majority share as #1 prescribed anti-amyloid treatment
    		$121M82%——
    SKYCLARYS (Global)
    Continued patient growth across all regions. U.S. Q3 revenue impacted by $6 million adjustment related to channel mix due to IRA changes. Efforts focused on reaching community-based Friedreich's ataxia patients in U.S.
    Countries available: 34
    		—30%——
    ZURZUVAE (U.S.)
    Continued strong growth driven by increased demand and expanded field team. Demonstrating healthcare providers' belief in rapid relief for postpartum depression.
    Breadth of writers growth: 19% quarter-over-quarterFirst-line prescriptions: 80%
    		$55M150%19%—
    Multiple Sclerosis (U.S.)
    Resilient performance mainly driven by strategic actions for VUMERITY growth and one-time events.
    Favorable gross-to-net adjustments: $38MVUMERITY favorable inventory dynamics: $22M
    		————
    Multiple Sclerosis (Ex-U.S.)
    Impacted by accelerated generic erosion of TECFIDERA, particularly in Europe. TYSABRI IV biosimilar impact offset by growing demand for subcutaneous formulation.
    TECFIDERA sequential net decrease (Europe): $28MTYSABRI subcutaneous formulation share (Europe): >50% of natalizumab patients
    		————

    Operational metrics

    17
    Launch products cumulative revenue
    $1.2B
    Trailing 12 months

    Revenue from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY.

    VUMERITY sales
    $0.5B
    First 9 months FY25

    Strong growth for VUMERITY, which has market exclusivity well beyond the end of the decade.

    Operating expense growth
    FlatYear-over-year
    FY25

    Despite new investments in launch products and R&D, OpEx growth remained flat.

    Development costs reduction
    25%
    Past 3 years

    Reduction in development costs while strengthening the pipeline.

    Research costs reduction
    40%
    Past 3 years

    Reduction in research costs while building a stronger pipeline.

    Cash and marketable securities balance
    $4B
    Q3 FY25 end

    Provides financial flexibility for strategic growth initiatives.

    Net debt balance
    $2.3B
    Q3 FY25 end

    Reflects the company's balance sheet strength.

    Alzheimer's blood tests
    350,00
    CY25

    Anticipated number of Alzheimer's blood tests this year, aiding in diagnosis.

    PET scans
    60,00075% increase compared to prior year
    Year-to-date

    Increase in PET scans, potentially attributable to increasing use of Alzheimer's blood diagnostics as a triaging tool.

    ZURZUVAE new patients treated
    80,000
    Today

    Number of women treated with ZURZUVAE today, highlighting the significant unmet need compared to 500,000 mothers suffering from PPD in the U.S.

    U.S. MS gross-to-net adjustments
    $38MFavorable impact
    Q3 FY25

    Benefited the U.S. MS business performance.

    VUMERITY favorable inventory dynamics
    $22M
    Q3 FY25

    Contributed to VUMERITY's strong performance.

    TECFIDERA Europe sequential net decrease
    $28MVersus prior quarter
    Q3 FY25

    Due to accelerated generic erosion, particularly in Germany.

    LEQEMBI China inventory build
    $35M
    Q2 FY25

    Represented roughly 6 months of demand in the region, impacting Q3 and expected Q4 sales.

    SKYCLARYS U.S. channel mix adjustment
    $6M
    Q3 FY25

    Impacted U.S. revenue in the context of IRA changes to Medicare.

    GAAP cost of sales
    $674MUp 6% year-over-year
    Q3 FY25

    Without the charge, GAAP cost of sales would have been approximately $570M, down 11% year-over-year.

    Pretax charge for Genentech claim
    $100M
    Q3 FY25

    Accrued in Q3 related to a judgment on Genentech's claim for past TYSABRI royalties and interest.

    Industry KPIs

    6
    MetricValueDetails
    Launch access metricsPositive early feedback
    Pipeline read out calendarMultiple readouts
    Regulatory approvals filingsApproved
    Therapeutic drug market shareMajority%
    Prescription volume new starts80%%
    Clinical trial efficacy safety dataConsistent clinically meaningful benefit

    Deals & partnerships

    3
    Alcyone TherapeuticsAcquisition of a company specializing in ASO administration

    Strategic acquisition to enhance ASO mode of administration, which is necessary for treating a number of diseases and will be much more convenient for patients taking intrathecal injections.

    Vanqua BioLicensing agreement for a preclinical C5aR1 antagonist

    Added a C5aR1 antagonist to the pipeline, offering opportunities to create a portfolio in immunology with multiple indications.

    UndisclosedAdditional research stage deals

    Expect to announce at least another one, if not two, further research stage deals by the end of the year.

    Risks & headwinds

    6
    LEQEMBI China inventory buildQ3 FY25 and Q4 FY25

    $35 million inventory build in Q2 FY25

    Mitigation: Half of the Q2 build was drawn down in Q3; demand in Q4 expected to be satisfied with remaining inventory, resulting in minimal revenue recognition.

    SKYCLARYS U.S. revenue impact from channel mixQ3 FY25

    $6 million adjustment

    Mitigation: Working to secure reimbursement in certain European and Latin American markets; focusing on reaching community-based patients in the U.S.

    Accelerated generic erosion of TECFIDERA in EuropeQ3 FY25, accelerating in Q4 FY25

    $28 million sequential net decrease in Q3 FY25

    Mitigation: Continuing to defend IP; expecting Q4 sequential impact to be roughly double the erosion seen in Q3.

    TYSABRI IV biosimilar entrant in U.S.Ongoing

    Increased competitive pressures

    Mitigation: Well prepared for biosimilar entrant; growing demand for subcutaneous formulation (no biosimilar alternative) offsetting impact in Europe.

    Pretax charge for Genentech claimQ3 FY25

    $100 million

    Mitigation: Accrued in Q3 FY25 related to a judgment on Genentech's claim for past TYSABRI royalties and interest.

    Competitive recruitment for litifilimab trialsOngoing

    Competitive recruitment environment

    Mitigation: Successfully fully enrolled both TOPAZ studies for litifilimab in SLE, pulling forward readouts to H2 2026, indicating strong physician interest.

    What to watch in Q4 FY25

    5

    Litifilimab Phase III readouts

    H2 2026
    CurrentStudies fully enrolled
    TargetReadouts in H2 2026

    Why it matters

    These readouts will determine the future of a key late-stage asset in the competitive lupus market.

    Importantly, as Chris mentioned, despite competitive recruitment for trials in the space, we have now fully enrolled both TOPAZ studies for litifilimab in SLE. This allows us to now pull forward📎 both expected readouts from these studies into next year 2026.

    Q&A highlights

    10

    How would a positive EVOKE trial impact the LEQEMBI franchise and Biogen's Alzheimer's portfolio, specifically regarding the need for a GLP-1 collaboration?

    Management believes a positive EVOKE trial would likely target primary care and earlier-stage patients, not directly affecting LEQEMBI's plaque-targeting mechanism. They are interested in a full Alzheimer's portfolio, including their BIIB080 program and brain shuttle technology, and would evaluate GLP-1s if data warrants, noting many are available. They also believe it would increase disease awareness.

    “I think if it is positive, we do think it's probably going to be more used in the primary care setting at an earlier stage. We'll have to see what the -- again, what the results are, but it doesn't seem like this would actually affect the amount of plaque.”

    asked by Umer Raffat · answered by Christopher Viehbacher

    2 min read5 chapters

    Detailed Narrative

    01

    New Product Growth and Market Creation

    Biogen's launch products, including LEQEMBI, SKYCLARYS, and ZURZUVAE, demonstrated significant year-on-year revenue growth of 67%, contributing $257 million in Q3 FY25. These products collectively generated nearly $1.2 billion in revenue over the last 12 months. Management emphasized that these are often first-in-class treatments requiring substantial market creation efforts, highlighting the commercial strength of the teams in building new markets rather than just capturing share in established ones.

    02

    Pipeline Acceleration and Strategic Focus

    The company is advancing a robust late-stage pipeline with 10 Phase III or Phase III-ready programs, including 5 new molecular entities. Notably, litifilimab's Phase III studies for SLE are fully enrolled, with readouts now expected in H2 2026, an acceleration attributed to strong physician interest. Biogen is also building its early-stage pipeline, initiating a Phase I study for BIIB142 (IRAK4 degrader) and expecting to add 3-4 more molecules in the next 18 months, alongside strategic BD activities like the Vanqua Bio collaboration.

    03

    Legacy Business Resilience and Efficiency

    The U.S. MS business showed resilient performance, with VUMERITY sales approaching $0.5 billion in the first nine months of FY25 and market exclusivity extending beyond the decade. This performance, along with favorable gross-to-net adjustments, partially offset the decline in the overall MS portfolio. The company remains on track to deliver $1 billion in gross savings and $800 million in net savings by the end of 2025 through its Fit-for-Growth initiative, while maintaining flat OpEx growth despite new investments.

    04

    Alzheimer's Disease Strategy and Biomarker Impact

    LEQEMBI continues to show strong sequential demand, with the recent approval and rollout of the IQLIK subcutaneous injection for maintenance offering patients an at-home option. The company is also advancing a rolling submission for subcutaneous initiation. Blood-based biomarkers are significantly impacting diagnosis, with up to 350,000 Alzheimer's blood tests expected this year and PET scan positivity rates increasing, streamlining the diagnostic pathway and potentially increasing patient throughput for treatment.

    05

    Immunology Expansion and Talent Acquisition

    Biogen is strategically expanding its focus on immunology, leveraging its historical experience in MS. Management views immunology as a core area with significant growth potential, particularly in rare immunology and areas overlapping with existing expertise like lupus. The ability to attract strong talent to new product development is seen as a positive indicator for future commercial success, reinforcing confidence in the pipeline's potential.

    AI-generated summary of the company’s earnings call. Not investment advice.